• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

    6/27/24 8:33:51 AM ET
    $AVAV
    $ELAN
    $GRFS
    $HIMS
    Aerospace
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVAV alert in real time by email

    U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday.

    Shares of Levi Strauss & Co. (NYSE:LEVI) fell sharply in today’s pre-market trading after the company reported mixed second-quarter financial results and issued FY24 EPS guidance with its midpoint below estimates.

    Levi Strauss reported quarterly earnings of 16 cents per share which beat the analyst consensus estimate of 11 cents by 45.45%. Quarterly sales came in at $1.44 billion, missing the analyst consensus estimate of $1.45 billion.

    Levi Strauss shares dipped 16.1% to $19.40 in pre-market trading.

    Here are some big stocks recording losses in today's pre-market trading session.

    • Immutep Limited (NASDAQ:IMMP) shares tumbled 29.6% to $1.9493 in pre-market trading after Baird maintained an Outperform rating on the stock but lowered its price target from $7 to $6.
    • Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) fell 20.6% to $6.95 in pre-market trading after the company announced the pricing of a $200 million public offering of 30,769,230 shares at $6.50 per share.
    • Walgreens Boots Alliance, Inc. (NASDAQ:WBA) shares declined 15.4% to $13.25 in pre-market trading after the company reported mixed third-quarter results and lowered 2024 guidance below consensus estimates.
    • International Paper Company (NYSE:IP) shares slipped 11.5% to $41.05 in pre-market trading after Suzano said it will not pursue a transaction involving the company.
    • Grifols, S.A. (NASDAQ:GRFS) shares fell 10.8% to $6.21 in pre-market trading.
    • Hims & Hers Health, Inc. (NYSE:HIMS) fell 11.2% to $19.15 in pre-market trading after gaining over 8% on Tuesday.
    • Elanco Animal Health Incorporated (NYSE:ELAN) shares declined 6.7% to $16.76 in pre-market trading.
    • AeroVironment, Inc. (NASDAQ:AVAV) shares fell 6.1% to $181.00 in pre-market trading after the company reported fourth-quarter financial results and issued FY25 EPS guidance below estimates.

    Now Read This: Over $30M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying

    Don't forget to check out our premarket coverage here

    Get the next $AVAV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVAV
    $ELAN
    $GRFS
    $HIMS

    CompanyDatePrice TargetRatingAnalyst
    Immutep Limited
    $IMMP
    3/13/2026Buy → Hold
    Maxim Group
    Immutep Limited
    $IMMP
    3/13/2026$1.00Outperform → Neutral
    Robert W. Baird
    Immutep Limited
    $IMMP
    3/13/2026Mkt Outperform → Mkt Perform
    Citizens
    AeroVironment Inc.
    $AVAV
    3/11/2026$450.00 → $400.00Buy
    Needham
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    AeroVironment Inc.
    $AVAV
    3/2/2026Strong Buy → Underperform
    Raymond James
    More analyst ratings

    $AVAV
    $ELAN
    $GRFS
    $HIMS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $AVAV
    $ELAN
    $GRFS
    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Immutep downgraded by Maxim Group

    Maxim Group downgraded Immutep from Buy to Hold

    3/13/26 12:51:00 PM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Immutep from Outperform to Neutral and set a new price target of $1.00

    3/13/26 8:45:21 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep downgraded by Citizens

    Citizens downgraded Immutep from Mkt Outperform to Mkt Perform

    3/13/26 8:45:11 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAV
    $ELAN
    $GRFS
    $HIMS
    SEC Filings

    View All

    SEC Form 8-K filed by Hims & Hers Health Inc.

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    3/11/26 5:21:18 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form DEFA14A filed by Levi Strauss & Co

    DEFA14A - LEVI STRAUSS & CO (0000094845) (Filer)

    3/11/26 4:16:51 PM ET
    $LEVI
    Apparel
    Consumer Discretionary

    SEC Form DEF 14A filed by Levi Strauss & Co

    DEF 14A - LEVI STRAUSS & CO (0000094845) (Filer)

    3/11/26 4:16:31 PM ET
    $LEVI
    Apparel
    Consumer Discretionary

    $AVAV
    $ELAN
    $GRFS
    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gustafsson Anders bought $1,000,036 worth of shares (26,092 units at $38.33) (SEC Form 4)

    4 - INTERNATIONAL PAPER CO /NEW/ (0000051434) (Issuer)

    3/12/26 5:16:02 PM ET
    $IP
    Paper
    Basic Materials

    Director Connor Christopher M bought $1,009,250 worth of shares (25,000 units at $40.37) (SEC Form 4)

    4 - INTERNATIONAL PAPER CO /NEW/ (0000051434) (Issuer)

    2/2/26 5:30:10 PM ET
    $IP
    Paper
    Basic Materials

    Chief Executive Officer Silvernail Andrew K bought $1,998,965 worth of shares (50,000 units at $39.98) (SEC Form 4)

    4 - INTERNATIONAL PAPER CO /NEW/ (0000051434) (Issuer)

    1/30/26 4:47:45 PM ET
    $IP
    Paper
    Basic Materials

    $AVAV
    $ELAN
    $GRFS
    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

    Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ("efti") in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol. Based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility. In

    3/13/26 8:00:00 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Autonomous Warfare Technologies Propel AI Defense Market Toward $30 Billion

    Rising geopolitical tensions, next-generation autonomous weapons systems, and rapid AI integration across defense platforms are projected to drive the market past $29 billion by 2035NEW YORK, March 11, 2026 /CNW/ -- Market News Updates News Commentary - The autonomous AI defense market is experiencing rapid growth as militaries increasingly integrate artificial intelligence, robotics, and machine learning into operational systems. Autonomous AI technologies enable defense platforms--such as drones, surveillance systems, and autonomous combat vehicles--to operate with minimal human intervention while enhancing decision-making speed, situational awareness, and mission efficiency. Governments a

    3/11/26 9:00:00 AM ET
    $AVAV
    $KTOS
    $LUNR
    Aerospace
    Industrials
    Military/Government/Technical
    Industrial Machinery/Components

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $AVAV
    $ELAN
    $GRFS
    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PAO Becklund Irene

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/13/26 4:20:59 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Policy Officer Autor Deborah M.

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/13/26 4:20:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Operating Officer Chi Michael

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/13/26 4:20:53 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $AVAV
    $ELAN
    $GRFS
    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AV Announces Retirement of Chief Financial Officer Kevin McDonnell

    AeroVironment, Inc. ("AV" or the "Company") (NASDAQ:AVAV), a global defense technology leader, today announced that Kevin McDonnell, Executive Vice President and Chief Financial Officer, has informed the Company of his decision to retire from AV, effective July 31, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223105811/en/McDonnell joined AV in 2020. During his tenure as CFO, AV strengthened its balance sheet, enhanced its financial and operational discipline, completed strategic acquisitions and organic growth initiatives, and reinforced its capital allocation framework to drive long-term shareholder value. "Kevin ha

    2/23/26 5:13:00 PM ET
    $AVAV
    Aerospace
    Industrials

    $AVAV
    $ELAN
    $GRFS
    $HIMS
    Financials

    Live finance-specific insights

    View All

    AeroVironment Announces Fiscal 2026 Third Quarter Results

    AeroVironment, Inc. (NASDAQ:AVAV) ("AeroVironment" or the "Company") reported today financial results for the fiscal third quarter ended January 31, 2026. Third Quarter Highlights: Third quarter revenue of $408.0 million Bookings of $2.1 billion and book-to-bill ratio of 1.6 for the first nine months of the fiscal year Record funded backlog of $1.1 billion "While our third quarter results were impacted by revenue timing and adjustments in our Space business, demand for our unique solutions remains robust," said Wahid Nawabi, AeroVironment chairman, president and chief executive officer. "Strong order flow and growth in funded backlog during the quarter are setting the stage fo

    3/10/26 4:10:00 PM ET
    $AVAV
    Aerospace
    Industrials

    Levi Strauss & Co. Completes Sale of Dockers® to Authentic Brands Group

    Levi Strauss & Co. (LS&Co.) (NYSE:LEVI), today announced the successful final closing, on February 27, 2026, of its previously disclosed sale of the Dockers® brand to Authentic Brands Group. The completion of this transaction sharpens LS&Co.'s focus on the Levi's® brand and Beyond Yoga®, simplifying the portfolio and strengthening the company's structural profitability. The divestiture aligns the company's assets with its highest-return growth opportunities and reinforces its disciplined capital allocation approach. Given the company's already strong cash position, LS&Co. is able to return the net cash proceeds to shareholders through existing accelerated share repurchase programs, while

    3/3/26 5:00:00 PM ET
    $LEVI
    Apparel
    Consumer Discretionary

    AV Issues Statement Regarding Active Negotiations for Contract Amendment to Support U.S. Space Force's SCAR Program

    Confident in ability to successfully deliver AV's systems ahead of competitors AeroVironment, Inc. ("AV" or the "Company") (NASDAQ:AVAV), a global defense technology leader, today issued the following statement regarding the U.S. Space Force's delivery of BADGER phased array antenna systems to support the Satellite Communications Augmentation Resource ("SCAR") program: We remain in active negotiations with the U.S. Space Force regarding AV's contract to deliver ground stations to support the SCAR program. AV appreciates that the contract was temporarily paused while both parties work together on a firm-fixed-price contract that provides a commercialized product solution with an expedite

    3/3/26 7:30:00 AM ET
    $AVAV
    Aerospace
    Industrials

    $AVAV
    $ELAN
    $GRFS
    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by International Paper Company

    SC 13G/A - INTERNATIONAL PAPER CO /NEW/ (0000051434) (Subject)

    11/14/24 1:22:34 PM ET
    $IP
    Paper
    Basic Materials

    Amendment: SEC Form SC 13G/A filed by Grifols S.A.

    SC 13G/A - Grifols SA (0001438569) (Subject)

    11/14/24 11:46:03 AM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/12/24 4:57:06 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care